The Technical Analyst
DarioHealth Corp [DRIO]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
DarioHealth Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.54% $1.210
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 35.63 mill |
| EPS: | -1.930 |
| P/E: | -0.630 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 29.44 mill |
| Avg Daily Volume: | 0.138 mill |
| RATING 2024-04-17 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.630 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.630 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.055 - 1.365 ( +/- 12.81%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-06 | Ben-david Zvi | Buy | 400 000 | Common Stock |
| 2024-03-06 | Shaked Yoav | Buy | 90 000 | Common Stock |
| 2024-03-06 | Anderson Richard Alan | Buy | 750 000 | Stock Option (right to buy) |
| 2024-03-06 | Anderson Richard Alan | Buy | 320 000 | Stock Option (right to buy) |
| 2024-03-06 | Kaplan Jon H. | Buy | 70 000 | Common Stock |
| INSIDER POWER |
|---|
| 99.68 |
| Last 96 transactions |
| Buy: 6 562 105 | Sell: 542 820 |
Forecast:
16:00 - $1.200
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.200
Forecast 2: 16:00 - $1.200
Forecast 3: 16:00 - $1.200
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.210 (2.54% ) |
| Volume | 0.0577 mill |
| Avg. Vol. | 0.138 mill |
| % of Avg. Vol | 41.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DRIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DRIO
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Latest Press Releases
2024-04-10 08:30:00 - Press Release
Dario Publishes Two New Peer-reviewed Studies Demonstrating Impact Of Digital Behavioral Health
Studies include a randomized controlled trial demonstrating significant reduction in perceived stress for teens new york , april 10, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today two new studies published in the leading peer-reviewed journal for digital health and medicine, journal of internet medicine (jmir), including a randomized controlled trial (rct) demonstrating the impact of a digital stress reduction program for teens. digital tools reduce stress and brooding in teens in a randomized control trial the first study uses the gold standard in research, a randomized controlled clinical trial (rct), to demonstrate the impacts of a self-guided digital mental health intervention (dmhi) for teens.
2024-04-02 08:30:00 - Press Release
Two National Employers Select Dario's Integrated Chronic Condition Solution To Improve Employee Health
Dario selected to provide integrated approach to improve employee cardiometabolic health - including support for those taking a glp-1 medication - musculoskeletal and behavioral health new york , april 2, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024. the first employer, a global private investment group, selected dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a glp-1.
2024-03-28 06:30:00 - Press Release
Dariohealth Reports Fourth Quarter And Full-year 2023 Financial And Operating Results
Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in b2c and strategic milestone revenue as the core b2b2c revenue increased. 2023 b2b2c, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction.
2024-03-21 08:30:00 - Press Release
Dariohealth To Report Fourth Quarter 2023 Results On Thursday, March 28th
Company to host conference call and webcast at 8:30am et new york , march 21, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio), a leader in the global digital therapeutics (dtx) market, announced today that it will release its financial results for the 4th quarter ended december 31, 2023, on thursday, march 28th, 2024, before the market opens and will host a conference call and webcast at 8:30 am eastern time. erez raphael, chief executive officer and rick anderson, president, will host the call.
2024-03-12 08:30:00 - Press Release
New Research From Dario Demonstrates Ability To Deliver Improved Health Outcomes With Integrated Solution For Members Managing Weight And Blood Glucose With Or Without Glp-1 Medications
Study presented at attd 2024 is the first of a planned series examining the impact of dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a glp-1 additional research presented demonstrated dario's ability to improve awareness of the importance of flu vaccines in member with type 2 diabetes new york , march 12, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio) (the "company"), a leader in the global digital therapeutics (dtx) market, announced today two new clinical studies presented at the 17th international conference on advanced technologies and treatments for diabetes (attd) 2024, held march 6 – 9 in florence, italy. examining evolving standards for metabolic health: improving outcomes with or without medication the introduction of glp-1s as an effective tool for both weight loss and diabetes management is evolving the standards of care for metabolic health conditions.
Latest News
2023-10-03 04:39:09 - Seeking Alpha
DarioHealth Disappoints, But A Better Future Is Ahead
DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company's competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.
2023-06-13 08:36:10 - MarketBeat
DarioHealth is an AI-Powered Digital Therapeutics Play
DarioHealth Co. NASDAQ: DRIO is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five common comorbidity conditions, including diabetes, weight loss, hypertension, musculoskeletal and behavioral health, across six domains: timing, tone, channel, content, frequency and intervention.
2023-05-11 15:34:06 - Seeking Alpha
DarioHealth Corp. (DRIO) Q1 2023 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Charles Rhyee - Cowen Rahul Rakhit - LifeSci Capital Benjamin Haynor - Alliance Global Partners David Grossman - Stifel Financial Operator Good morning, and welcome to the DarioHealth First Quarter 2023 Results Call. All participants are in a listen only mode [Operator Instructions] After today's presentation, there will be opportunity to ask questions.
2023-03-09 14:06:13 - Seeking Alpha
DarioHealth Corp. (DRIO) Q4 2022 Results Conference Call
DarioHealth Corp. (NASDAQ:DRIO ) Q4 2022 Results Conference Call March 9, 2023 8:30 PM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson - President Conference Call Participants Charles Rhyee - TD Cowen Alexander Nowak - Craig-Hallum Capital Group Rahul Rakhit - LifeSci Capital Ben Haynor - Alliance Global Partners David Grossman - Stifel Operator Greetings, and welcome to the DarioHealth Fourth Quarter 2022 Results Call. At this time, all participants are in a listen only mode.
2023-03-02 08:00:00 - PRNewsWire
DarioHealth to Report Fourth Quarter 2022 Results on Thursday, March 9th
Company to host conference call and webcast at 8:30 am ET NEW YORK , March 2, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 9, 2023, before market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, Rick Anderson, President, and Zvi Ben-David, Chief Financial Officer will host the call.
2023-02-02 02:37:32 - Seeking Alpha
DarioHealth: January Rally Looks To Be Exhausting (Technical Analysis)
DarioHealth rallied off a low in December and since raced to new highs. Market generated data suggests the rally could extend over the coming weeks to months.
2022-11-17 11:44:08 - Seeking Alpha
DarioHealth: Market Sentiment Shift Post Q3 Numbers, Revise To Speculative Buy
We've revised our rating on DarioHealth to a buy, with consideration to tactical allocation for equity portfolios. DRIO's Q3 numbers came in strong with upsides versus consensus at the top and bottom lines.
2022-11-15 12:14:04 - Seeking Alpha
DarioHealth Corp. (DRIO) Q3 2022 Earnings Call Transcript
DarioHealth Corp. (NASDAQ:DRIO ) Q3 2022 Results Conference Call November 15, 2022 8:30 AM ET Company Participants Glenn Garmont - IR Erez Raphael - CEO Rick Anderson - President Conference Call Participants Charles Rhyee – Cowen Rahul Rakhit - LifeSci Capital David Grossman – Stifel Ben Haynor - Alliance Global Partners Chase Knickerbocker - Craig-Hallum Operator Good day, everyone, and welcome to the DarioHealth Third Quarter 2022 Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
2022-08-15 13:00:51 - Seeking Alpha
DarioHealth Corp (DRIO) CEO Erez Raphael on Q2 2022 Results - Earnings Call Transcript
DarioHealth Corp (NASDAQ:DRIO ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Glenn Garmont - LifeSci Advisors Erez Raphael - CEO & Director Richard Anderson - President & GM, North America Conference Call Participants Charles Rhyee - Cowen and Company Alexander Nowak - Craig-Hallum Rahul Rakhit - LifeSci Capital David Grossman - Stifel, Nicolaus & Company Benjamin Haynor - Alliance Global Partners Nathan Weinstein - Aegis Capital Corporation John Vandermosten - Zacks Small-Cap Research Operator Greetings, and welcome to the DarioHealth Corp. Second Quarter 2020 Results Conference Call. [Operator Instructions].
2022-06-15 16:26:02 - Benzinga
Dario Health (DRIO) Poised To Inflect Upon Full Launch of National Health Plan
Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan - Fundamentals: Company positioned to avoid dilutive financing after recent $50M credit facility with OrbiMed - Catalysts: Company is guiding for a full launch of a large national insurer, by end of June -.